期刊
ONCOTARGETS AND THERAPY
卷 14, 期 -, 页码 3537-3544出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S311661
关键词
pancreatic cancer; pembrolizumab; complete response; PD-L1; locally advanced; immune checkpoint inhibitor
PDAC, a deadly cancer type, is generally resistant to immune therapies despite advances in systemic therapies. Preoperative radiation and immunotherapy may improve treatment outcomes for PDAC patients, but more data is needed for further support.
Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据